2024 CTAD Presentation:
ALTITUDE-AD: Use of a Validated p-tau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Participants with Early Alzheimer’s Disease
2023 CTAD Poster:
Recruitment and Eligibility of a Diverse Study Population in INTERCEPT-AD: A phase I trial of Aβ oligomer-targeting ACU193 in early Alzheimer’s disease.
2023 CTAD Presentation:
INTERCEPT-AD phase 1 insights and findings from the investigation of ACU193, a monoclonal antibody targeting soluble Aβ oligomers.
2023 CTAD Poster:
INTERCEPT-AD: ACU193 CSF pharmacokinetics in early Alzheimer’s disease.
2023 CTAD Poster:
Incorporating the Study Participant’s Voice into Early Development of ACU193 for Early Alzheimer’s Disease: A Qualitative Interview Study Following Participation in the INTERCEPT-AD Study.
2023 CTAD Poster:
ACU193-sAβO Complex Measurement in CSF: Additional Analyses Using a Sensitive Assay of Target Engagement for the sAβO-Selective Antibody ACU193 in INTERCEPT-AD.
2022 CTAD Poster:
Critical evaluation and comparison of biomarker values in commercial CSF with Lumipulse® to support assay development for clinical trials.
2021 CTAD Presentation:
Phase 1 trial design for ACU193, a monoclonal antibody that selectively binds soluble Aβ oligomers.
2019 CTAD Poster
Synaptic intervention in Alzheimer’s disease: soluble Aβ oligomer directed ACU193 monoclonal antibody therapeutic for treatment of early Alzheimer’s disease.
